Showing 1671-1680 of 6936 results for "".
Authority Tags - Protecting Your Content
https://practicaldermatology.com/topics/practice-management/authority-tags-protecting-your-content/18678/Practices need to maintain a strong online presence in order to build brand awareness. Google author tags is one strategy that is emerging as a robust marketing tool that supports building a strong online presence. What are author tags, how do they work, and how do they protect your content? The EkwPD Asks: The Future of Cosmetic Surgery
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/pd-asks-the-future-of-cosmetic-surgery/18680/PD Asks Joel Schlessinger, MD about the future of cosmetic dermatology. Watch Dr. Schlesinger discuss his views about how the speciality has evolved and grown with solid scientific research about treatments including fillers and toxins. He also discusses his meeting, Cosmetic Surgery Forum. Watch oGold Mettle: Dr. Michael Gold Talks Multifaceted Practice with Dr. Joel Cohen
https://practicaldermatology.com/topics/practice-management/gold-mettle-dr-michael-gold-talks-multifacted-practice-with-dr-joel-cohen/18868/Dr. Michael Gold's thriving Nashville practice includes a busy medical practice, a medical spa, and a research center. Plus, he's involved in teaching and educational ventures globally. How does he do it all—and stay on schedule? Dr. Joel L. Cohen finds out.Off-label Uses for Biologics
https://practicaldermatology.com/topics/psoriasis/off-label-uses-for-biologics/18964/Derm Insider Bonus Content: Host Neal Bhatia speaks with guests Alice Gottlieb, MD, Harold Farber, MD, and James Ulery, MD about various potential off-label uses for current and investigational systemic psoriasis therapies.Neotensil®: A Novel, Noninvasive Solution That Reduces the Appearance of Under-Eye Bags
https://practicaldermatology.com/topics/practice-management/neotensil-a-novel-noninvasive-solution-that-reduces-the-appearance-of-under-eye-bags/19058/Neotensil is the only noninvasive solution clinically proven to reduce the appearance of under-eye bags within an hour, with benefits that last up to 16 hours. Doris Day, MD, discusses the benefits of Neotensil, as well as patient selection, staff training and how to incorporate this unique and effeThe Importance of Planning
https://practicaldermatology.com/topics/practice-management/the-importance-of-planning/19082/Failing to plan is planning to fail, say Jay A. Shorr, BA, MBM-C, CAC I-V and Mara Shorr, BS, CAC II-V of The Best Medical Business Solutions. They tell aesthetic practices how to lay the foundation for success in minimally invasive procedures.The Importance of Diversity in Clinical Trials
https://practicaldermatology.com/issues/april-2025/the-importance-of-diversity-in-clinical-trials/35606/The disproportionate representation of certain segments of the population in clinical trials is no secret, and research has shown that psoriasis studies are the least racially diverse of all dermatology studies in the US.The Biosimilar Revolution: A Look at the Potential Impact
https://practicaldermatology.com/issues/april-2025/the-biosimilar-revolution-a-look-at-the-potential-impact/35596/With many biosimilars expected to gain regulatory approval in coming months and years, Practical Dermatology interviewed Collin Blattner, DO, FAAD—an editorial board member and double-board–certified dermatologist who owns Clearchoice Dermatology, which has 12 locations in Oregon and Washington—abouSkin Coverage as a Medical Benefit
https://practicaldermatology.com/series/c-suite-chats/skin-coverage-as-a-medical-benefit/35559/Mike Jafar, Founder and CEO of Joya Health, talks about the importance of having skin coverage as a medical benefit, trends in dermatology, and the driver behind the rising rates of melanoma.Addressing Equity Gaps in Psoriasis Research
https://practicaldermatology.com/series/c-suite-chats/addressing-equity-gaps-in-psoriasis-research/33151/LaShell Robinson, Head, Global Feasibility and Trial Equity for Takeda, discusses the disproportionate underrepresentation of certain racial and ethnic groups in clinical trials, especially for psoriasis, and how Takeda is seeking to close those gaps in recent Phase 3 trials.